FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1993096411> ?p ?o ?g. }

• W1993096411 endingPage "B1" @default.
• W1993096411 startingPage "B1" @default.
• W1993096411 abstract "Background: Mutant KRAS is detected in 20–25% of non-small cell lung carcinomas (NSCLC) and represents one of the most common oncogenic drivers of this disease. NSCLC tumors with oncogenic KRAS respond poorly to currently available therapies necessitating the pursuit of new treatment strategies. Heat shock protein 90 (Hsp90) is a molecular chaperone required for the maturation and stability of hundreds of client proteins, many of which are known oncogenic drivers or effectors of such proteins. Inactivation of Hsp90 results in the simultaneous inhibition of multiple oncogenic signaling pathways, making Hsp90 a highly attractive therapeutic target. Ganetespib is a second generation, small molecule Hsp90 inhibitor currently being evaluated in multiple clinical trials. Recent results from a Phase 2 trial with ganetespib revealed that >60% of patients with KRAS mutant NSCLC exhibited tumor shrinkage at 8 weeks, indicating that ganetespib has promising potential to benefit this disease. Aims: To further understand the actions of ganetespib in mutant KRAS NSCLC tumors, preclinical studies were executed in a diverse panel of KRAS mutant NSCLC cell lines to: (1) Investigate whether ganetespib is effective in suppressing critical cell signaling nodes responsible for KRAS-driven NSCLC cell survival and (2) Assess whether ganetespib can synergize with both clinical agents targeted against these signaling nodes and standard of care chemotherapies. Results: Ganetespib displayed potent anticancer activity across 15 KRAS mutant NSCLC cell lines assayed in vitro, with an average IC50 of 24 nM. Combining ganetespib with anti-mitotics, alkylating agents or topoisomerase inhibitors resulted in an increase in cell death of up to 44, 61 and 26%, respectively, versus monotherapy. At the molecular level, ganetespib induced the destabilization of several KRAS substrates, including BRAF and CRAF, leading to inactivation of their downstream effectors followed by programmed cell death. Ganetespib effectively suppressed the growth of human KRAS mutant NSCLC tumor xenografts in vivo; however, ganetespib did not induce tumor regression. In light of this, we sought to investigate whether inhibitors targeting KRAS driven signaling nodes would confer greater sensitivity to ganetespib. In vitro, combinations of low dose ganetespib with either MEK or PI3K/mTOR inhibitors consistently resulted in greater activity than monotherapy, up to 77% and 42%, respectively. Furthermore, ganetespib suppressed activating feedback loops that occur in response to MEK and PI3K/mTOR inhibition, providing a rationale for the enhanced combinatorial activity. To validate these results, in vivo combinations were performed with ganetespib and a PI3K/mTOR inhibitor in KRAS mutant NSCLC xenografts. While both agents promoted tumor shrinkage on their own, considerable improvement in tumor growth inhibition was observed in the combination arm. Conclusions: Ganetespib, a potent inhibitor of Hsp90, has shown encouraging evidence of clinical activity, including tumor shrinkage in patients with KRAS mutant NSCLC. In vitro, ganetespib exhibited potent anticancer activity in NSCLC cells harboring a diverse spectrum of KRAS mutations due in part to degradation and inactivation of critical KRAS signaling effectors. Combination with targeted therapies that overlap with these signaling nodes led to enhanced anticancer activity in vitro and in mouse models of KRAS mutant NSCLC. Taken together, these results could have interesting clinical utility in patients with KRAS mutant NSCLC." @default.
• W1993096411 created "2016-06-24" @default.
• W1993096411 creator A5008756739 @default.
• W1993096411 creator A5016382860 @default.
• W1993096411 creator A5038282112 @default.
• W1993096411 creator A5056912217 @default.
• W1993096411 creator A5057196078 @default.
• W1993096411 date "2012-02-01" @default.
• W1993096411 modified "2023-09-27" @default.
• W1993096411 title "Abstract B1: Targeting KRAS mutant NSCLC with the Hsp90 inhibitor ganetespib" @default.
• W1993096411 doi "https://doi.org/10.1158/1078-0432.12aacriaslc-b1" @default.
• W1993096411 hasPublicationYear "2012" @default.
• W1993096411 type Work @default.
• W1993096411 sameAs 1993096411 @default.
• W1993096411 citedByCount "1" @default.
• W1993096411 countsByYear W19930964112012 @default.
• W1993096411 crossrefType "journal-article" @default.
• W1993096411 hasAuthorship W1993096411A5008756739 @default.
• W1993096411 hasAuthorship W1993096411A5016382860 @default.
• W1993096411 hasAuthorship W1993096411A5038282112 @default.
• W1993096411 hasAuthorship W1993096411A5056912217 @default.
• W1993096411 hasAuthorship W1993096411A5057196078 @default.
• W1993096411 hasConcept C104317684 @default.
• W1993096411 hasConcept C121608353 @default.
• W1993096411 hasConcept C126322002 @default.
• W1993096411 hasConcept C205260736 @default.
• W1993096411 hasConcept C2775932338 @default.
• W1993096411 hasConcept C2777560012 @default.
• W1993096411 hasConcept C2781187634 @default.
• W1993096411 hasConcept C502942594 @default.
• W1993096411 hasConcept C526805850 @default.
• W1993096411 hasConcept C55493867 @default.
• W1993096411 hasConcept C71924100 @default.
• W1993096411 hasConcept C86803240 @default.
• W1993096411 hasConceptScore W1993096411C104317684 @default.
• W1993096411 hasConceptScore W1993096411C121608353 @default.
• W1993096411 hasConceptScore W1993096411C126322002 @default.
• W1993096411 hasConceptScore W1993096411C205260736 @default.
• W1993096411 hasConceptScore W1993096411C2775932338 @default.
• W1993096411 hasConceptScore W1993096411C2777560012 @default.
• W1993096411 hasConceptScore W1993096411C2781187634 @default.
• W1993096411 hasConceptScore W1993096411C502942594 @default.
• W1993096411 hasConceptScore W1993096411C526805850 @default.
• W1993096411 hasConceptScore W1993096411C55493867 @default.
• W1993096411 hasConceptScore W1993096411C71924100 @default.
• W1993096411 hasConceptScore W1993096411C86803240 @default.
• W1993096411 hasIssue "3 Supplement" @default.
• W1993096411 hasLocation W19930964111 @default.
• W1993096411 hasOpenAccess W1993096411 @default.
• W1993096411 hasPrimaryLocation W19930964111 @default.
• W1993096411 hasRelatedWork W2005100930 @default.
• W1993096411 hasRelatedWork W2100370559 @default.
• W1993096411 hasRelatedWork W2115647596 @default.
• W1993096411 hasRelatedWork W2131615886 @default.
• W1993096411 hasRelatedWork W2313514471 @default.
• W1993096411 hasRelatedWork W2315978372 @default.
• W1993096411 hasRelatedWork W2403308793 @default.
• W1993096411 hasRelatedWork W2587457642 @default.
• W1993096411 hasRelatedWork W2744254482 @default.
• W1993096411 hasRelatedWork W2744901703 @default.
• W1993096411 hasRelatedWork W2887131868 @default.
• W1993096411 hasRelatedWork W2889171823 @default.
• W1993096411 hasRelatedWork W2895923466 @default.
• W1993096411 hasRelatedWork W2900680219 @default.
• W1993096411 hasRelatedWork W2900848249 @default.
• W1993096411 hasRelatedWork W2944353312 @default.
• W1993096411 hasRelatedWork W2969509842 @default.
• W1993096411 hasRelatedWork W2973796265 @default.
• W1993096411 hasRelatedWork W3099372775 @default.
• W1993096411 hasRelatedWork W3206992268 @default.
• W1993096411 hasVolume "18" @default.
• W1993096411 isParatext "false" @default.
• W1993096411 isRetracted "false" @default.
• W1993096411 magId "1993096411" @default.
• W1993096411 workType "article" @default.